US Guideline Updates in Dyslipidemia Management

Recent recommendations of US guidelines highlight the importance of treating dyslipidemia earlier in life, refining cardiovascular risk assessment, and adopting lower LDL cholesterol targets to reduce long-term exposure to atherogenic lipoproteins and prevent atherosclerotic cardiovascular disease (ASCVD). Lifestyle counseling should begin in youth, with early pharmacologic therapy considered for individuals with familial hypercholesterolemia and for young adults with LDL-C ≥160 mg/dL or a strong family history of premature ASCVD. For primary prevention in adults aged 30–79 years, clinicians are encouraged to use the newer American Heart Association PREVENT equations instead of older risk models and follow the “CPR” framework: calculate 10-year ASCVD risk, personalize the estimate by incorporating additional patient-specific risk enhancers, and reclassify risk when appropriate using tools such as coronary artery calcium (CAC) scoring before reassessing treatment decisions. LDL-lowering therapy may be considered for those with borderline 10-year risk (3% to <5%) and is recommended after clinician–patient discussion for intermediate risk (5% to <10%). Treatment goals again emphasize both LDL-C and non–HDL-C targets along with percentage LDL reduction according to risk level. Additional biomarkers can refine risk assessment: apolipoprotein B testing helps identify residual atherogenic lipoprotein risk, especially in patients with elevated triglycerides (>200 mg/dL), diabetes, or very low achieved LDL-C (<70 mg/dL), while lipoprotein(a) should be measured at least once since levels ≥125 nmol/L (50 mg/dL) significantly increase ASCVD risk and may warrant more aggressive LDL lowering. CAC scoring—particularly in men aged ≥40 years and women aged ≥45 years—can further guide treatment decisions by improving risk classification. LDL-lowering therapy is recommended for primary prevention in adults aged 40–75 years with diabetes, stage 3 or 4 chronic kidney disease, or HIV regardless of baseline LDL-C, and pharmacologic therapy may still be considered after age 75 along with lifestyle modification. In secondary prevention, most patients with established ASCVD—especially those at very high risk—should aim for LDL-C <55 mg/dL and non–HDL-C <85 mg/dL, while a smaller subset at lower risk may target LDL-C <70 mg/dL. For patients with persistently elevated triglycerides, statins remain the cornerstone of therapy alongside lifestyle changes, and additional triglyceride-lowering treatments may be necessary in severe hypertriglyceridemia, particularly when triglyceride levels reach ≥1000 mg/dL to reduce the risk of pancreatitis as well as cardiovascular events. Source: https://www.jacc.org/